Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Progression-free Survival
62%
Chest Pain
58%
Immune Checkpoint Inhibitors
56%
Asthma
54%
Immune Checkpoint Inhibitor Therapy
46%
SRT1720
43%
Lung Cancer
38%
Tumor
33%
Small Cell Lung Cancer
32%
Older Men
31%
SIRT1 Activator
29%
Sirtuin 1 (SIRT1)
25%
Programmed Death-ligand 1 Expression
24%
Clinical Parameters
21%
Egfr
21%
Patient Characteristics
20%
Knowledge Dissemination
20%
Procaterol Hydrochloride
20%
Monotherapy
19%
Programmed Death-ligand 1 (PD-L1)
19%
Non-squamous
19%
Squamous Cell
19%
Chest CT
19%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
18%
Clinical Course
18%
Systemic Therapy
17%
Ischemic Heart Disease
17%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
17%
Postoperative Recurrence
16%
Headache
15%
Primary Lesion
15%
Lung Adenocarcinoma
15%
T790M mutation
15%
Chest Radiograph
15%
Pembrolizumab
14%
Monosodium Glutamate
14%
Lipolytic Enzymes
14%
Vascular Dilation
14%
Hepatopulmonary Syndrome
14%
Mouse Model of Asthma
14%
Irinotecan
14%
Bioelectrical Impedance Analysis
14%
Reduced Expression
14%
Cryptogenic Organizing Pneumonia
14%
Fatty Liver
14%
PD-1 Inhibitor
14%
CD4 T-lymphocyte Count
14%
Visceral Adipose Tissue
14%
Ovalbumin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
60%
Immune Checkpoint Inhibitor
58%
Progression Free Survival
53%
Neoplasm
45%
N [2 [3 (1 piperazinylmethyl)imidazo[2,1 B]thiazol 6 Yl]phenyl] 2 Quinoxalinecarboxamide
43%
Asthma
41%
Small Cell Lung Cancer
36%
Disease
35%
Chemotherapy
32%
Programmed Death 1 Ligand 1
32%
Thorax Pain
29%
Epidermal Growth Factor Receptor
28%
Overall Survival
27%
Monotherapy
23%
Recurrent Disease
21%
Retrospective Study
18%
Disease Course
16%
Inflammation
16%
Lung Cancer
16%
Hepatopulmonary Syndrome
14%
Glutamate Sodium
14%
Irinotecan
14%
Fatty Liver
14%
Carcinoma
14%
Mouse Model
14%
Ovalbumin
14%
Wheezing
14%
Sirtuin 1
14%
Radiation Pneumonia
14%
Ischemic Heart Disease
14%
Lung Metastasis
14%
Breast Cancer
14%
Epidermal Growth Factor Receptor Kinase Inhibitor
14%
Adverse Event
13%
Procaterol
12%
Fibrosis
12%
Minoxidil
10%
Cisplatin
10%
Emphysema
9%
Nonalcoholic Fatty Liver
9%
Lactate Dehydrogenase
8%
Pembrolizumab
8%
Lung Adenocarcinoma
7%
Autoimmune Hemolytic Anemia
7%
Sarcomatoid Carcinoma
7%
Chest Tightness
7%
Osimertinib
7%
Necitumumab
7%
Observational Study
5%
Medicine and Dentistry
Immune Checkpoint Inhibitor
65%
Non Small Cell Lung Cancer
53%
Asthma
49%
Lung Cancer
45%
Thorax Pain
43%
Lung
29%
Disease
26%
Progression Free Survival
24%
Neoplasm
19%
T-Helper Cell
18%
Disease Course
17%
Systemic Therapy
17%
Retrospective Study
17%
Recurrent Disease
16%
Patient Characteristics
16%
Headache
15%
Lung Adenocarcinoma
15%
Thorax Radiography
15%
Hepatopulmonary Syndrome
14%
Local Therapy
14%
Bronchiolitis Obliterans Organizing Pneumonia
14%
T Lymphocyte
14%
Liver Injury
14%
Resuscitation
14%
Vasodilatation
14%
Carcinoma
14%
Surgery
14%
Osteoarthropathy
14%
SRT1720
14%
Sirtuin1
14%
Wheeze
14%
Ischemic Heart Disease
14%
Radiation Pneumonia
14%
Breast Cancer
14%
Lung Metastasis
14%
Tumor Cell
14%
Cell Migration
14%
Metastatic Carcinoma
13%
Pembrolizumab
13%
Procaterol
13%
Dyspnea
12%
Fibrosis
12%
Chemotherapy
12%
Cisplatin
10%
Overall Survival
9%
Digital Clubbing
9%
Emphysema
9%
Arthralgia
9%
Monotherapy
9%
Programmed Death 1 Ligand 1
9%